At a glance
| Dalbavancin | Dalvance; acute bacterial skin infections |
|---|---|
| Oritavancin | Orbactiv; adult acute bacterial skin infections |
| Telavancin | Vibativ; selected skin and hospital-acquired lung infections |
| Shared focus | Susceptible Gram-positive bacteria |
| Important distinction | Different renal, interaction, and monitoring considerations |
Overview
These three lipoglycopeptides share a useful class relationship, but each is a separate active ingredient with its own clinical trials, product formulation, and prescribing information. Dalbavancin and oritavancin are associated with prolonged exposure that can reduce administration frequency in appropriate infection care. Telavancin has a different treatment pattern and important renal and pregnancy-related warnings. Clinical selection depends on the organism, infection site, susceptibility, kidney function, other medicines, and available alternatives. None is a cosmetic skin-repair peptide. Their activity against resistant bacteria does not justify use for an unconfirmed infection or imply coverage of every pathogen.
How it works
All three interfere with Gram-positive bacterial cell-wall processes; lipid-associated structural features influence their antibacterial behavior and pharmacokinetics. Oritavancin and telavancin also have membrane-related actions described in their labels. Shared class membership does not erase differences in clearance, laboratory-test interference, or adverse effects. Each drug therefore requires its own product information even when an educational page compares the class.
Dalbavancin trial evidence
The DISCOVER trials found dalbavancin noninferior to vancomycin with optional transition to linezolid for acute bacterial skin infections. In the pooled analysis, early clinical responses were approximately 80% in both groups. Noninferiority supports a particular treatment comparison; it is not evidence that all three lipoglycopeptides have identical efficacy or safety.
Supporting sources [1]
Drug-specific limitations
Oritavancin can interfere with coagulation tests and creates specific limitations around intravenous unfractionated heparin. Telavancin carries boxed warnings concerning nephrotoxicity, embryo-fetal toxicity, and increased mortality in certain pneumonia patients with pre-existing renal impairment. Dalbavancin has its own hypersensitivity, infusion, liver-test, and renal considerations. These differences are central to prescribing decisions.
Why the infection site matters
The labeled skin-infection settings are specific bacterial syndromes, not all redness or wounds. Telavancin’s hospital-acquired pneumonia indication is restricted to susceptible Staphylococcus aureus when alternatives are unsuitable. A grouped educational page should help compare agents while directing the reader to the correct individual label, rather than implying a universal antibiotic choice.
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Three distinct lipoglycopeptide antibiotics grouped for comparison.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- DISCOVER trials: dalbavancin versus conventional therapy for skin infection ↗Clinical trial source · Checked 2026-10-27
- DailyMed: Dalvance prescribing information ↗Regulatory source · Checked 2026-10-27
- DailyMed: Orbactiv prescribing information ↗Regulatory source · Checked 2026-10-27
- DailyMed: Vibativ prescribing information ↗Regulatory source · Checked 2026-10-27